Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Empagliflozin Compared With Linagliptin in New-onset Diabetes Mellitus After Kidney Transplantation

NCT03642184 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT03642184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03642184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Empagliflozin Compared With Linagliptin in New-onset Diabetes Mellitus After Kidney Transplantation
Lead sponsor
RenJi Hospital
Phase
Phase 4
Overall status
Terminated
Start date
July 14, 2018
Completion date
January 31, 2019
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant; complications, new onset diabetes after transplant